文献速递类风湿关节炎脊柱关节炎

生物制剂启用与转换与抗抑郁及抗焦虑药物使用相关:基于42 815例真实世界炎症性风湿病患者的数据

Introduction and switching of biologic agents are associated with antidepressant and anxiolytic medication use: data on 42 815 real-world patients with inflammatory rheumatic disease.
PubMed 文献 · RMD Open · 2020-01-01

该研究基于全国电子处方数据库,纳入42 815例接受bDMARDs的类风湿关节炎、银屑病关节炎和强直性脊柱炎患者,分析生物制剂启用或转换与抗抑郁/抗焦虑药物使用的关联。结果显示,bDMARD启用与抗抑郁药(OR 1.248)和抗焦虑药(OR 1.178)使用相关,bDMARD转换与抗抑郁药(OR 1.502)和抗焦虑药(OR 1.161)使用相关,且独立于年龄、性别、诊断及糖皮质激素/ csDMARD使用。

要点

  • bDMARD启用与抗抑郁药使用相关(OR 1.248,95%CI 1.153-1.350,p<0.0001)。
  • bDMARD转换与抗抑郁药使用相关(OR 1.502,95%CI 1.370-1.646,p<0.0001)。
  • 临床决策启用或转换bDMARD时应考虑抑郁和焦虑的影响。

核心结论

  • 在真实世界环境中,炎症性风湿病患者启用和转换bDMARD均与心境障碍(抑郁/焦虑)治疗存在关联。

研究设计与样本

  • 基于全国电子处方数据库(注册10 012 604人,覆盖99%人口)的回顾性队列分析。
  • 纳入2年期间(2016年8月至2018年7月)接受bDMARDs的类风湿关节炎(n=12 002)、银屑病关节炎(n=5465)和强直性脊柱炎(n=6423)患者,共42 815例。
  • 采用多变量回归分析比较启用或转换bDMARDs患者与持续使用csDMARDs或同一bDMARD患者的抗抑郁/抗焦虑药物使用。

主要发现

  • bDMARD启用与抗抑郁药使用相关(OR 1.248,95%CI 1.153-1.350,p<0.0001)。
  • bDMARD启用与抗焦虑药使用相关(OR 1.178,95%CI 1.099-1.263,p<0.0001)。
  • bDMARD转换与抗抑郁药使用相关(OR 1.502,95%CI 1.370-1.646,p<0.0001)。
  • bDMARD转换与抗焦虑药使用相关(OR 1.161,95%CI 1.067-1.264,p=0.001)。
  • 上述关联均独立于年龄、性别、基础疾病诊断及合并糖皮质激素或csDMARD使用。

临床怎么用

  • 面对活动性炎症性风湿病患者,在决定启用或转换bDMARD时,应始终考虑抑郁和焦虑的影响。

局限性

  • 原文未明确报告因果关系的不确定性,仅指出关联存在但因果关系不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Depression and anxiety are linked bi-directionally with inflammatory rheumatic diseases (IRDs) activity, which in turn, depends on subjective patient reported outcomes that can be distorted by comorbid mood disorders. We tested the hypothesis that introduction and/or switching of biologic agents for IRDs are associated with treatment for depression and/or anxiety, by analysing real-world data. METHODS: Using a country-wide electronic prescription database (10 012 604 registered, 99% population coverage), we captured almost all patients with rheumatoid arthritis (n=12 002), psoriatic arthritis (n=5465) and ankylosing spondylitis (n=6423) who received biologic disease modifying anti-rheumatic drugs (bDMARDs) during a 2-year period (8/2016-7/2018). Concomitant antidepressant/anxiolytic medication use was documented in patients who started or switched bDMARDs and compared with those who remained on conventional synthetic (cs)DMARDs or the same bDMARD, respectively, by multivariate regression analysis. RESULTS: Two-year data analysis on 42 815 patients revealed that bDMARD introduction was associated with both antidepressant [OR: 1.248, 95% CI 1.153 to 1.350, p<0.0001] and anxiolytic medication use [OR: 1.178, 95% CI 1.099 to 1.263, p<0.0001]. Moreover, bDMARD switching was also associated with antidepressant [OR: 1.502, 95% CI 1.370 to 1.646, p<0.0001] and anxiolytic medication use [OR: 1.161, 95% CI 1.067 to 1.264, p=0.001]. Notably, all these associations were independent of age, gender, underlying disease diagnosis and concomitant glucocorticoid or csDMARD medication use. CONCLUSION: In real-world settings, both introduction and switching of bDMARDs in patients with IRDs were associated with the presence of mood disorders. Although a causal relationship is uncertain, the impact of depression and anxiety should always be considered by physicians facing the decision to introduce or switch bDMARDs in patients with active IRDs.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Bournia VK, Tektonidou MG, Vassilopoulos D, et al. Introduction and switching of biologic agents are associated with antidepressant and anxiolytic medication use: data on 42 815 real-world patients with inflammatory rheumatic disease. RMD Open. 2020. PMID: 32978302. doi:10.1136/rmdopen-2020-001303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。